Sign in to view content

Evaluating Intravitreal ANX007, a Novel C1q Inhibitor, in the Treatment of GA Secondary to AMD: The ARCHER Study

David S. Boyer, MD

Video
Published 2021

Related

Treat-and-Extend Versus Bimonthly Dosing With Aflibercept for the Treatment of Diabetic Macular Edema, 1-Year Outcomes (EVADE Study)
Dilsher S. Dhoot, MD
Annual Meeting Talks
2018
A Comparison of the Anatomical Efficacy of Brolucizumab Versus Aflibercept in nAMD Patients: Matched 16-Week Results From the HAWK and HARRIER Studies
Pravin U. Dugel, MD
Annual Meeting Talks
2018
Improvement of Worsening in Diabetic Retinopathy Through 2 Years in a Randomized Trial
Susan B. Bressler, MD, FASRS
Updates from the Field
2017

Category: AMD-Non-Neovascular

See more